Samsung Biologics Quarterly Profit Jumps – Key Margin Insights Samsung Biologics is a Buy: operating profit rose 39.7% despite revenue decline, but labor disputes may create volatility until next-quarter results confirm stabilization. 2026년 05월 21일 English
